WINTON GROUP Ltd Cuts Stake in Viking Therapeutics, Inc. $VKTX

WINTON GROUP Ltd reduced its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 65.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,762 shares of the biotechnology company’s stock after selling 44,938 shares during the period. WINTON GROUP Ltd’s holdings in Viking Therapeutics were worth $836,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Raleigh Capital Management Inc. grew its stake in shares of Viking Therapeutics by 58.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 347 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viking Therapeutics during the third quarter valued at $38,000. Fifth Third Bancorp boosted its position in shares of Viking Therapeutics by 169.3% during the fourth quarter. Fifth Third Bancorp now owns 1,077 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 677 shares during the last quarter. Lodestone Wealth Management LLC purchased a new stake in shares of Viking Therapeutics during the fourth quarter valued at $39,000. Finally, GAMMA Investing LLC boosted its position in shares of Viking Therapeutics by 71.0% during the fourth quarter. GAMMA Investing LLC now owns 1,195 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 496 shares during the last quarter. 76.03% of the stock is owned by hedge funds and other institutional investors.

Viking Therapeutics Price Performance

Viking Therapeutics stock opened at $29.23 on Wednesday. Viking Therapeutics, Inc. has a one year low of $22.96 and a one year high of $43.15. The business’s fifty day moving average is $32.11 and its 200 day moving average is $32.99. The stock has a market capitalization of $3.39 billion, a PE ratio of -7.06 and a beta of 0.69.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same quarter in the prior year, the company earned ($0.41) earnings per share. As a group, sell-side analysts expect that Viking Therapeutics, Inc. will post -4.7 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on VKTX. Cantor Fitzgerald dropped their price objective on Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Wolfe Research began coverage on Viking Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating on the stock. Morgan Stanley set a $95.00 price objective on Viking Therapeutics in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Monday, April 20th. Finally, BTIG Research reaffirmed a “buy” rating and set a $125.00 price objective on shares of Viking Therapeutics in a research report on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $93.60.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.